WXXWY:OTCMKTS
Wuxi Biologics Cayman ADR
$12.33
arrow_downward
-1.81%(-0.23) 1D
Oct 19, 9:49:05 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for WXXWY...
Open
$12.19
High
$12.33
Low
$12.19
Mkt. cap
198.43B
Avg. vol.
64.29K
Volume
467.00
52-wk high
$14.80
52-wk low
$7.30
Beta
0.01
Shares outstanding
2.06B
No. of employees
15K
Open
$12.19
High
$12.33
Low
$12.19
Mkt. cap
198.43B
Avg. vol.
64.29K
Volume
467.00
52-wk high
$14.80
52-wk low
$7.30
Beta
0.01
Shares outstanding
2.06B
No. of employees
15K
News stories
From web sources and news partners
FOREX.com
·
8 minutes ago
DJIA and Bitcoin Outlook: Are Charts Facing Contrarian Sentiment Risks?
Quartz
·
31 minutes ago
Tech stocks rebound as Nasdaq rises 1% and the Dow slips in early trading
Yahoo Finance
·
24 minutes ago
Goldman Sachs is still betting on a nice year-end rally for the S&P 500
TradingView
·
2 hours ago
Dow upgraded by Bank of America as higher oil prices boost chemical outlook
Profile
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
About Wuxi Biologics Cayman ADR